Head-to-head comparisons

Retatrutide vs Tirzepatide for Women: Which Is Right for You?

Medically reviewed by Editorial Medical Review, MD, NAMS-CMP · Updated July 2026

Quick answer

Tirzepatide (Zepbound) is an FDA-approved dual agonist that produced up to about 20.9% mean weight loss in the SURMOUNT-1 trial. Retatrutide is an investigational triple agonist that reached roughly 24% in a phase 2 trial but is not FDA-approved or available. For women today, only tirzepatide is a real prescribing option.

Dual agonist vs triple agonist

Tirzepatide, sold as Zepbound for weight and Mounjaro for type 2 diabetes, activates two gut-hormone receptors: GIP and GLP-1. Retatrutide adds a third target, the glucagon receptor, which is why it is described as a triple agonist. In theory, engaging glucagon can raise energy expenditure on top of the appetite reduction both drugs share.

The practical difference in 2026 is regulatory, not just pharmacologic. Tirzepatide has completed the trials the FDA requires and is approved. Retatrutide is still being studied, so its full efficacy and safety picture, including any sex-specific findings, is not settled.

How the weight-loss numbers compare

In SURMOUNT-1, adults on the highest tirzepatide dose lost up to about 20.9% of body weight over 72 weeks. In a phase 2 retatrutide trial, the highest dose produced roughly 24% mean weight loss at 48 weeks. These come from separate trials at different phases, not a head-to-head study, so the numbers cannot be compared directly.

A larger headline percentage in an earlier-phase trial is not proof of superiority. Phase 3 trials exist to confirm whether early results hold up in bigger, longer studies, which is exactly what retatrutide has not yet completed.

GI tolerability and side effects

Both drug classes most commonly cause gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation, which is why doses are increased slowly. Retatrutide reported a similar gastrointestinal profile in phase 2, but long-term tolerability data are still limited compared with the larger tirzepatide record.

What this means for women right now

The tirzepatide label warns that it may reduce the effectiveness of oral birth control and advises a backup or non-oral method for 4 weeks after starting and after each dose increase. Retatrutide has no approved label and therefore no such published guidance; clinical trials generally require effective contraception for participants.

Both drug classes advise against use in pregnancy. Because retatrutide is not available outside trials, any product sold online as retatrutide is unapproved and not a verified medicine.

Key points

  • Tirzepatide is FDA-approved for weight (Zepbound); retatrutide is investigational and not available.
  • SURMOUNT-1 showed up to ~20.9% for tirzepatide; retatrutide reached ~24% in phase 2 only.
  • Different trials and phases mean the percentages are not directly comparable.
  • Tirzepatide carries an oral-contraceptive warning; retatrutide has no approved label.

Molecule facts (canonical explainers)

This is a decision guide. For the plain-fact explainer of each molecule (mechanism, FDA status, dosing cautions), see:

Providers we review in this area

Editorial reviews only — not treatment recommendations. Prescribing decisions rest with a licensed clinician. For the full directory, see all GLP-1 for women providers.

  • Form Health — Board-certified obesity medicine physicians prescribing GLP-1s. Often insurance-covered — among the most affordable options when insurance applies.
  • Plushcare GLP-1 — Primary care telehealth that prescribes Wegovy and Zepbound when clinically appropriate. Insurance-friendly.
  • Knownwell — Weight-inclusive primary care with GLP-1 access. Designed by clinicians frustrated with typical obesity medicine model — focuses on the whole person.

Cost

Tirzepatide (Zepbound) self-pay vials run from about $349 to $599 per month via LillyDirect. Retatrutide has no commercial price because it is not available.

See the full cost breakdown in our How much does Zepbound cost?.

Related questions

Frequently asked questions

Is retatrutide stronger than tirzepatide?
Retatrutide reached roughly 24% mean weight loss in a phase 2 trial versus up to about 20.9% for tirzepatide in SURMOUNT-1, but these are separate trials at different phases. That is not proof it is stronger; phase 3 trials are still confirming retatrutide results.
Can women get retatrutide instead of tirzepatide?
No. Retatrutide is investigational and only available through registered clinical trials. Tirzepatide (Zepbound) is FDA-approved and prescribable, so it is the only real option of the two right now.
Do both drugs affect birth control?
The tirzepatide label warns it may reduce oral-contraceptive effectiveness and advises a backup method for 4 weeks after starting and after dose increases. Retatrutide has no approved label, so there is no published contraception guidance for it.

Sources

Every efficacy, safety, and price claim above resolves to an FDA label, published trial, guideline, or manufacturer / GoodRx pricing page. External links open in a new tab.

Keep reading

ClearHormones updates these guides as FDA status and pricing change. Verify current approval status and pricing on the manufacturer or FDA page before acting.